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Abstract 
Multiple myeloma is characterized by accumulation of malignant plasma cells in the bone 
marrow. Most patients suffer from an osteolytic bone disease, caused by increased bone 
degradation and reduced bone formation. Bone morphogenetic protein 4 (BMP4) is important 
for both pre- and postnatal bone formation and induces growth arrest and apoptosis of myeloma 
cells. BMP4-treatment of myeloma patients could have the potential to reduce tumor growth 
and restore bone formation. We therefore explored BMP4 gene therapy in a human-mouse 
model of multiple myeloma where humanized bone scaffolds were implanted subcutaneously 
in RAG2-/- γC-/-mice. Mice were treated with adeno-associated virus serotype 8 BMP4 vectors 
(AAV8-BMP4) to express BMP4 in the liver. When mature BMP4 was detectable in the 
circulation, myeloma cells were injected into the scaffolds and tumor growth was examined by 
weekly imaging. Strikingly, the tumor burden was reduced in AAV8-BMP4 mice compared 
with the AAV8-CTRL mice, suggesting that increased circulating BMP4 reduced tumor 
growth. BMP4-treatment also prevented bone loss in the scaffolds, most likely due to reduced 
tumor load. To delineate the effects of BMP4 overexpression on bone per se, without direct 
influence from cancer cells, we examined the unaffected, non-myeloma femurs by µCT. 
Surprisingly, the AAV8-BMP4 mice had significantly reduced trabecular bone volume, 
trabecular numbers, as well as significantly increased trabecular separation compared with the 
AAV8-CTRL mice. There was no difference in cortical bone parameters between the two 
groups. Taken together, BMP4 gene therapy inhibited myeloma tumor growth, but also reduced 
the amount of trabecular bone in mice. Our data suggest that care should be taken when 
considering using BMP4 as a therapeutic agent.  
Key words: BMPs/TGF-βs, Tumor-induced bone disease, Osteoclasts, Osteoblast, Cancer 
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Introduction 
Multiple myeloma is a hematological cancer caused by accumulation of malignant plasma cells 
in the bone marrow (1). Nearly all patients suffer from a severe  osteolytic bone disease, causing 
pain and fractures (2). The bone disease is caused by increased osteoclast activity and a lack of 
bone repair due to too few and dysfunctional osteoblasts (2). Currently, bisphosphonates are 
the most common drugs used to treat the bone disease, and there is a lack of treatment options 
that can promote bone formation. New, efficient drugs to treat myeloma have been developed 
the last decades, including immunomodulatory agents, proteasome inhibitors, histone 
deacetylase inhibitors, and monoclonal antibodies (3). Nevertheless, multiple myeloma remains 
an incurable disease (4).   
 
Bone morphogenetic proteins (BMPs) is a large subgroup of ligands in the transforming growth 
factor (TGF)-β family (5). In vitro, several BMPs induce growth arrest and apoptosis in multiple 
myeloma cell lines as well as in primary myeloma cells from patients (6-11). BMP-signaling is 
also important for both pre- and postnatal bone formation.(12) For example, combined deletion 
of BMP2 and BMP4 in mesenchymal stem cells (MSC) leads to severely impaired osteogenesis 
in mice (13) and inhibiting BMP-signaling reduces osteoblast differentiation in mouse and 
human cells (14-16). On the other hand, two separate studies found increased bone mass and 
bone strength in mice treated with soluble BMPR1A-Fc fusion protein (17,18). BMPR1A-Fc 
has high affinity to BMP2 and BMP4 and acts as a decoy receptor that inhibits their binding to 
receptors on the surface of cells. Thus, the effects of a given BMP in the context of multiple 
myeloma is not entirely clear.  In this study we wanted to clarify if BMP4 could have therapeutic 
potential in multiple myeloma patients, by preventing tumor growth and restoring bone 
homeostasis. We therefore evaluated the effects of AAV-based BMP4 gene therapy in a human-
mouse scaffold model of multiple myeloma.  
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Materials and Methods 
Cell culture and reagents 
The human myeloma cell line KJON (19) was cultured in RPMI with 5 % heat inactivated 
human serum (HS) and 2 ng/mL interleukin (IL)-6 (Gibco, Thermo Fisher Scientific, Waltham, 
MA, USA). In vitro experiments with KJON cells were performed with 2 % HS in RPMI and 
IL-6 (1 ng/mL). The mouse myeloma cell line NS0 was generously provided by Dr Z. Eshhar 
(Weizmann Institute of Science, Israel), and the cells were grown in 10 % FCS in RPMI. All 
cells were cultured at 37 oC in a humidified atmosphere containing 5 % CO2 and were tested 
for mycoplasma every three months. Recombinant murine (rm) BMP4 (Cat# 5020-BP), 
recombinant human (rh) BMP4 (Cat# 314-BP), rhM-CSF (Cat# 216-MC), neutralizing BMP4 
antibody (Cat# MAB50201), and rat isotype control (MAB006) were from R&D Systems (Bio-
Techne, Abingdon, UK). 
 
Generation of iRFP-labeled KJON myeloma cells 
The iRFP sequence was amplified from piRFP (gift from Vladislav Verkhusha, Addgene 
plasmid# 31857; http://n2t.net/addgene:31857; RRID:Addgene_31857)(20). with PCR primers 
with overhangs containing restriction sites for SpeI and NotI (Sigma). pLVX-EF1α-IRES-
ZsGreen1 (Cat# 631982, Clontech, Takara Bio USA, CA, USA) was cut with SpeI and NotI 
restriction enzymes, treated with FastAP, and ligated with the iRFP PCR product, using T4 
DNA ligase (all Fermentas, Thermo Fisher Scientific). The resulting plasmid, pLVX-EF1α-
iRFP-IRES-ZsGreen1, was used together with TransLenti Viral Packaging Mix (Open 
Biosystems) and Genejuice (Novagen, Merck Life Science AS, Oslo, Norway) to transfect 
293T packaging cells (Open Biosystems, Thermo Fisher Scientific). Supernatants containing 
lentivirus were used to transduce the KJON myeloma cell line. Positively transduced cells 
expressed both iRFP and ZsGreen1 fluorescent proteins and were sorted on a FACSAria™ 
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Fusion flow cytometer (BD Biosciences, San Jose, CA, USA) to obtain a pure population of 
iRFP-positive cells for in vivo studies.   
 
Cell viability in vitro 
Cell viability was measured using the Cell Titer-Glo assay (Promega, Madison, WI, USA), that 
measures the ATP content in wells. Cell lines were seeded in 96 well optical plates (104 
cells/well) and treated as indicated in the figure legends. Cell Titer-Glo reagent was added 
following the manufacturer’s instructions and luminescence was measured using Victor 1420 
multilabel counter (PerkinElmer Inc., Waltham, MA, USA). To distinguish between effects on 
cell division and cell death, we measured apoptosis by annexin V labelling. In brief, cells were 
seeded in 96 well plates (5 x 104 cells/well) and treated as indicated in the figure legends. The 
cells were stained using Apotest FITC kit (Nexins Research, Kattendijke, The Netherlands). 
Then, cells were incubated with annexin V FITC (0.2 µg/mL) on ice for one hour. Propidium 
iodide (PI) (1.4 µg/mL) was added five minutes before cells were analyzed using an LSRII flow 
cytometer (BD Biosciences, San Jose, CA, USA). Cells negative for both annexin-V and PI 
staining were considered viable. 
 
RAG2-/- γC-/- 
We used RAG2-/- γC-/- BALB/c female mice as described previously (21). The mice lack B, T 
and NK cell immunity and were kept in specific pathogen free (SPF) unit. Here the mice were 
housed in IVC-cages, with free access to bedding material, nesting material and enrichment 
objects. Mice were given sterile food (RM1 #801002, Special Diets Services, Essex, UK,) and 
water ad libitum, and were caged in groups of 3-5 mice. Mice were maintained at a room 
temperature of 21-22 C and 55 % humidity with a 12 hr light/dark cycles including 1 hr 
dusk/dawn. All mice were of approximately the same age at the beginning of experiments. 
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Human-mouse scaffold myeloma model and imaging 
We used a modified version of a previously described xenograft mouse model with a humanized 
bone environment (21). Briefly, human bone marrow-derived mesenchymal stromal cells 
(hMSC) from healthy donors were seeded on biphasic calcium phosphate (BCP) scaffolds and 
differentiated towards osteoblasts for 1 week in vitro. Then, four cell-containing scaffolds were 
inserted subcutaneously on the back of 20 12-week old RAG2-/- γC-/- female mice and left for 
further differentiation of the cells. After 8 weeks, mice were treated with recombinant adeno-
associated virus (AAV) of serotype 8, AAV8-CTRL (n=10) or AAV8-BMP4 (n=10) (1012 viral 
particles in 100 µL), by tail vein injections. These viruses contain the human α1-antitrypsin 
(hAAT1) promoter to ensure transgene expression in the liver. The AAVs were produced and 
purified as described previously.(22) After another 2 weeks, the mice were whole-body 
irradiated using a dose of 2 Gy photons on the day before injection of 106 KJON cells into three 
of the scaffolds. The fourth scaffold was used as a non-tumor cell control. An overview of the 
experimental set-up is shown in Figure 1. Treatment with AAV is regarded relatively safe,(23) 
and in line with this, AAV8 treatment did not cause any adverse events in mice. However, one 
mouse in the AAV8-BMP4 group passed away for unknown reason. Tumor load (iRFP 
intensity) was measured weekly using Pearl Imager and analyzed with the accompanying Image 
Studio software (LI-COR Biosciences, Lincoln, NE, USA). At week 6 post myeloma cell 
injection, the mice were sacrificed, and serum, organs and bones were harvested. All mice were 
euthanized before tumors reached 1 cm3 (- scaffold) or when the tumor affected animal well-
being. Animal handling and procedures were approved by the Norwegian food safety authority 
(FOTS7692). The experiment was not blinded. 
 
Western blotting 
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Mouse liver cells were prepared by cutting the liver in smaller pieces using a scalpel, before 
they were dissociated using gentleMACS™ Dissociator (Miltenyi Biotech, Bergisch Gladbach, 
Germany). Pelleted cells were lysed in lysis buffer (50 mM Tris-HCl (pH 7.5), 1 % IGEPAL 
CA-630 (Sigma-Aldrich), 150 mM NaCl, 10 % glycerol, 1 mM Na3VO4, 50 mM NaF and 
protease inhibitor cocktail (Roche, Basel, Switzerland)). For serum samples, 5 uL of serum was 
used per well. The samples were denatured in NuPage LDS sample buffer (Invitrogen, Thermo 
Fisher Scientific) supplemented with 25 mM dithiothreitol (DTT) for 10 min at 70°C before 
they were separated on 4-12 % Bis-Tris polyacrylamide gels with MES buffer (Invitrogen), and 
transferred to a nitrocellulose membrane using the iBlot Dry Blotting System (Invitrogen). The 
membrane was blocked using nonfat dry milk (5 %) diluted in Tris-buffered saline with 0.01 % 
Tween 20 (TBS-T). The primary antibodies were: Mouse anti-BMP4 (Cat# ab93939, 
RRID:AB_10562295) and mouse anti-GAPDH (Cat# ab8245, RRID:AB_2107448) (Abcam, 
Cambridge, UK). Blots were incubated with horseradish peroxidase (HRP) conjugated 
secondary antibodies (DAKO Cytomation, Glostrup, Denmark) and developed with 
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific). Images 
were obtained with Odyssey FC and analyzed using Image Studio Software (LI-COR). 
 
Real-time RT-PCR 
Liver cells were dissociated as described in the western blotting section and mRNA was isolated 
from the cells. Femurs from all mice were harvested, flushed and kept in liquid nitrogen until 
further processing. The femurs were then homogenized using Metal Bead Lysing Matrix (MP 
Biomedicals, LLC, OH, USA) and Trizol (Thermo Fisher Scientific). Samples of mRNA were 
reversely transcribed and RT-PCR analysis was performed using TaqMan Gene Expression 
Arrays (Applied Biosystems, Thermo Fisher Scienctific) as described previously.(24) The 
primers are listed in Supplementary Table 1. Genes with a Ct value ≥ 36 were considered as not 
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detected. StepOne Software v2.1 (Applied Biosystems) was used to analyze the samples and 
the comparative Ct method was used to estimate relative changes in gene expression using 
Gapdh as housekeeping gene. 
 
Osteoclast differentiation 
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors using 
Lymphoprep (Axis-Shield, Oslo, Norway). CD14+ cells were further purified using magnetic 
beads (Miltenyi). Cells were seeded out in 96 well plates and cultured in aMEM with 10 % heat 
inactivated HS and M-CSF (30 ng/mL) for 2 days. At this point rhBMP4 (20-200 ng/mL) was 
added as indicated in the figure legend. When multinuclear cells were visible with light 
microscopy, cells were fixed and stained for TRAP using Acid Phosphatase, Leukocyte (TRAP) 
kit, (Merck KGaA, Darmstadt, Germany). TRAP positive cells with 3 or more nuclei were 
counted. 
 
Scaffold bone analysis 
The scaffolds were harvested at end point and decalcified using Osteosoft (Merck). After 
approximately 4 weeks, when scaffolds were soft to the touch, they were embedded in paraffin, 
sectioned (3.5µm) and stained with hematoxylin and eosin. Images were acquired using Nikon 
Microscope ECLIPSE Ci-S. The amount of bone and total scaffold perimeter were quantified 
using NIS Elements (BR 4.00.00, Nikon). 
 
uCt analysis  
Femurs were harvested and examined by ex vivo µCT using a µCt scanner (Skyscan 1176, 
Bruker, Kontich, Belgium) as described.(25) Images were acquired using the following 
settings: 18‐µm voxel resolution, 0.5‐mm aluminum filter, 50‐kV voltage, and 500‐µA current, 
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252 ms exposure time, rotation 0.5 degrees, frame averaging = 4. Images were reconstructed 
and analyzed using SkyScan software programs NRecon (version 1.6.9.4), DataViewer (version 
1.4.4), and CT Analyzer (version 1.12.10.0). Femoral trabecular analysis region of interest 
(ROI) was determined by identifying the distal end of the femur and calculating 10 % of the 
total femur length toward the femora mid‐shaft, where we then analyzed an ROI of 15 % of the 
total femur length. Analysis of bone structure was completed using adaptive thresholding (mean 
of minimum and maximum values) in CT Analyzer. Thresholds for analysis were determined 
manually based on grayscale values (0–255, where 0 = black and 255 = white) and were set as 
36 to 255. Cortical analyses were performed 35 % above the distal end of the femur toward the 
femora mid‐shaft, also with a 15 % ROI with the threshold values set as 80 to 255. 
Images were generated using CtVox (version 3.3) (Skyscan 1.1.6.0). 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 7.04. To compare two groups we used 
the unpaired, two-tailed t-test. To compare more than 2 groups we performed 1- or 2-way 
ANOVA with Dunn’s test or Bonferroni Post hoc test, respectively. Results were considered 
significant when p<0.05.  
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Results 
 
BMP4 gene therapy reduces tumor growth in vivo 
BMP4 induces apoptosis in approximately half of primary myeloma cell samples tested, as well 
as in a few myeloma cell lines (7,9). Here, we wanted to use a cell line which is both sensitive 
to BMP4 and relies on a supportive tumor microenvironment to grow in vivo. KJON is a slowly 
proliferating, IL-6 dependent cell line that is sensitive to BMP9 (10,19). BMP4 induces 
apoptosis in this cell line in vitro (Figure 2A, B). To investigate if BMP4 would also reduce in 
vivo tumor growth, we utilized an adeno-associated virus vector expressing BMP4 under the 
control of a liver-specific promoter (AAV8-BMP4) (22) in a human-mouse scaffold model of 
multiple myeloma (21). AAV8-BMP4 or control (AAV8-CTRL) viral particles were injected 
into the tail veins of mice that were implanted with scaffolds seeded with human bone marrow-
derived MSCs8 weeks earlier. 2 weeks after virus injection, when recombinant BMP4 was 
detectable in blood plasma (data not shown), fluorescently labeled KJON myeloma cells were 
injected directly into 3 out of 4 scaffolds in each mouse.  
Tumor growth was examined by weekly imaging, until 6 weeks after myeloma cell injection 
when the mice were euthanized. We found a significant reduction in tumor load in AAV8-
BMP4 mice compared with the AAV8-CTRL mice (p<0.01, Figure 2 C, D). At this time point, 
serum levels of BMP4 were high (50-200 ng/mL) in the AAV8-BMP4 mice (Figure 2E). The 
BMP4 was biologically active, since addition of sera obtained from the AAV8-BMP4-treated 
mice to the murine myeloma cell line NS0, led to reduction in cell viability. Adding BMP4-
neutralizing antibody restored viability (Figure 2F). In contrast, NS0 viability was not affected 
by sera obtained from AAV8-CTRL mice. Further supporting successfully transduction, we 
could detect the pro-form of BMP4 in liver lysates from AAV8-BMP4 mice, but not from 
AAV8-CTRL mice (Supplementary Figure 1A, B), and we also observed that AAV8-BMP4 
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treatment increased downstream BMP targets such as Smad7 and Id1 in the liver 
(Supplementary Figure 1 C, D). To examine if the BMP4 transgene would alter the expression 
of endogenous BMP4 or other BMPs, we analyzed the mRNA expression of mouse Bmp4, 
Bmp2, Bmp6, Gdf2 (BMP9) in the liver. The expression of these did not change (Supplementary 
Figure 1 E-H). Taken together, these data demonstrated that AAV8-BMP4 gene therapy lead 
to the production of high amounts of circulating, biologically active BMP4 that reduced tumor 
growth. 
 
Continuous drug exposure may generate acquired resistance in multiple myeloma (26). To 
examine if the tumor cells became resistant to BMP4 during the treatment, we isolated live cells 
from tumors from both AAV8-BMP4 and AAV8-CTRL mice. Cells from both groups were 
equally sensitive to BMP4 treatment in vitro, indicating that they did not acquire resistance to 
BMP4 during the experiment (Supplementary Figure 2).  
 
BMP4-treatment rescues bone loss in the scaffolds 
Human bone is generated on the scaffolds by osteoblasts that differentiate from human MSCs 
seeded on the scaffolds before implantation (21). In this model, similar to what happens in 
multiple myeloma, bone formation in the scaffolds is impaired by the presence of myeloma 
cells (21). This was also the case here, as we found less bone in scaffolds with myeloma cells 
compared with the scaffolds without myeloma cells (Figure 3A, left, p<0.05). Interestingly, this 
difference was lost in the AAV8-BMP4-treated mice (Figure 3A, right panel). This could be 
explained by an increased availability of BMP4 in the AAV8-BMP4 treated mice, promoting 
osteoblast differentiation and bone formation in the humanized bone scaffolds. However, when 
we quantified amount of bone in scaffolds without tumors, we found no significant difference 
between AAV8-BMP4 treated mice compared with AAV8-CTRL mice (Figure 3A).  Thus, it 
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is likely that the beneficial effect on bone formation in the scaffolds is due to reduced tumor 
burden in AAV8-BMP4-treated mice. 
 
High circulating levels of BMP4 reduces mouse trabecular bone volume 
The myeloma cells were confined to the scaffolds, as we could not detect plasma cells in the 
spleen or murine bone marrow when examined by imaging or flow cytometry (data not shown). 
We next aimed to investigate the effects of the elevated levels of circulating BMP4 on bone 
alone, without influence from the cancer cells. First, we established that the tumors did not 
affect the mouse bones by some soluble factor secreted from the tumor cells. This was done by 
comparing cortical and trabecular bone parameters in femurs obtained from un-implanted 
control mice (untreated RAG2-/- γC-/-) with the AAV8-CTRL mice. As shown in Table 1 there 
was no difference in trabecular or cortical bone parameters between the groups of mice when 
examined by ex vivo μCT. Thus, the presence of tumor/scaffold had no apparent effect on mouse 
bone and the femurs in the AAV8-CTRL mice can be considered “naïve”. 
 
We next examined the effect of BMP4 on mouse bone by comparing properties of femurs 
obtained from AAV8-BMP4 treated mice with the AAV8-CTRL treated mice. Surprisingly, the 
AAV8-BMP4 mice had significantly reduced trabecular bone volume (bone volume per tissue 
volume; % BV/TV, p=0.017), trabecular numbers (Tb.N/mm, p=0.016) as well as significantly 
increased trabecular separation (Tb.Sp (mm)) compared with the AAV8-CTRL mice 
(p=0.0005, Figure 3B-E). Thus, high levels of circulating BMP4 were detrimental for trabecular 
bone. In contrast, there were no differences in cortical bone parameters between the two groups 
(Supplementary Figure 3). Moreover, since RAG2-/- γC-/- mice are immunocompromised, we 
performed a small study using the same viral vectors in female immunocompetent C57BL6/N 
mice (n=4/5 group). Although the reduction in bone volume (% BV/TV) in AAV8-BMP4 
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compared to AAV8-CTRL mice was not significant, there was a significant increase in 
trabecular separation (Tb.Sp) and a reduction in trabecular numbers (Tb.N/mm) in AAV8-
BMP4 treated mice compared to AAV8-CTRL mice, supporting that high levels of BMP4 may 
have a negative impact on trabecular bone also in immunocompetent mice (Supplementary 
Figure 4).   
 
Effects of BMP4 gene therapy on osteoblasts and osteoclasts.  
In an attempt to determine whether the BMP4-induced effects on bone were caused by increased 
bone resorption or decreased bone formation we measured the bone degradation marker C-
terminal telopeptide of Type I collagen (CTX-1) and bone formation marker type I pro-collagen 
N-terminal pro-peptide (PINP) in mouse sera (Supplementary Figure 5). However, there were 
no significant differences between the groups. We also analyzed the murine femurs to examine 
if high BMP4 levels had altered osteoblast differentiation. Again, mRNA expression of 
osteocyte- and osteoblast-specific markers (Sclerostin (Sost), Dickkopf-related protein 1 
(Dkk1), Runt-related transcription factor 2 (Runx2) and Osterix (Sp7)) did not differ between 
the groups (Supplementary Figure 6). Although this may suggest that osteoblast differentiation 
was not significantly affected, the variation in gene expression within groups were high, which 
makes it hard to conclude on this matter.   
 
For the osteoclast-specific markers, Cathepsin K (Ctsk) and Nuclear factor of activated T-cells, 
cytoplasmic 1 (Nfatc1), we found a significant increase in Ctsk in the AAV8-BMP4 mice 
(p<0.05, Figure 3F, G). We therefore investigated if BMP4 had an osteoclast-promoting effect 
in vitro. Indeed, addition of recombinant human (rh) BMP4 to CD14+ osteoclast-precursors 
increased osteoclast differentiation (Ctrl vs rhBMP4 (200 ng/mL), p<0.05, Figure 3H). Taken 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/575159doi: bioRxiv preprint first posted online Mar. 13, 2019; 
15 
 
together our results infer that BMP4 has a negative impact on bone, at least in part, by increasing 
osteoclast numbers.  
 
 
Discussion 
In this study we wanted to explore BMP4 gene therapy as a potential treatment for multiple 
myeloma in a human-mouse model. We found that BMP4 gene therapy inhibited myeloma 
tumor growth, but surprisingly reduced trabecular bone in mice.  
 
BMPs, like TGF-β, usually act as tumor suppressors (5). In multiple myeloma, several different 
BMPs inhibit growth in vitro (6-10). The abundance of different BMPs in the bone marrow is 
not known. It was shown that BMP6 mRNA is expressed by both normal and malignant plasma 
cells, and that high levels of BMP6 in myeloma cells was associated with a favorable prognosis 
in multiple myeloma patients (27). This suggests that BMPs can have anti-tumor effects in 
patients. We show here that BMP4 treatment inhibited tumor growth in vivo, in line with 
previous studies examining effects of BMP4 on tumor cell survival in vitro. Importantly, more 
than half of the patient-derived primary cells we tested in vitro were sensitive to BMP4, which 
implies that BMP4 could have beneficial effects in a large group of patients (7,9). Multiple 
myeloma is a very heterogeneous disease, and the malignant cells harbor different genetic 
aberrations (27). About 50 % of all myeloma patients have cancer cells that are hyperdiploid 
(27). Despite this high number of hyperdiploid cells, very few cell lines have been established 
with this genotype. Here, we used the hyperdiploid myeloma cell line, KJON, which has a 
relatively slow growth rate and relies on addition of recombinant IL-6 in the absence of a 
supporting microenvironment, thus resembling what takes place in patients (19). Such cells are 
usually not able to grow in a mouse bone marrow microenvironment (28), but in this model the 
human mesenchymal cells provide the support needed. The model also recapitulates the tumor-
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induced bone loss, which is a characteristic feature of myeloma. Thus, we here show that BMP4 
gene therapy inhibited myeloma growth in a relevant in vivo model. Importantly, we found that 
reduction of tumor size by BMP4 gene therapy had a beneficial effect on bone, as it prevented 
loss of bone in tumor-affected bone, although it did not promote bone formation. However, it 
is important to note that the human-mouse scaffold model cannot be used to study tumor-
induced bone loss in load-bearing bone. 
 
The bone-inducing effect of BMPs has been known since the 1960s, and BMP2, BMP4-7 and 
BMP9 have all been appreciated for their osteogenic potential.(12,29) We were therefore 
surprised to find that trabecular bone was significantly reduced in AAV8-BMP4 treated mice 
compared with AAV8-CTRL mice, and that high levels of circulating BMP4 failed to promote 
bone formation in the scaffolds. To examine if this effect was somehow specific for RAG2-/- 
γC-/- BALB/c mice, we performed a small study in immunocompetent C57BL6/N mice using 
the same AAV8-BMP4 vector. Also in these mice, overexpression of BMP4 decreased the 
amount of trabecular bone, while cortical bone was unaffected. Our results are thus in contrast 
to previous studies demonstrating that BMPs, including BMP4, promote osteoblast 
differentiation and bone formation.(13-15,30). Further, in another study researchers found that 
injection of AAV2-BMP4 into the skeletal muscle of immunocompetent rats resulted in new 
bone induced by endochondral ossification already at week 3 (31). In contrast to our study, 
where we used AAV8-BMP4 to increase circulating levels of BMP4, it is likely that the AAV2-
BMP4 mainly increased BMP4 locally, thus explaining the different outcomes. On the other 
hand, and in line with our data, BMP4 overexpression in bone caused severe osteopenia and 
increased osteoclast number in mice (32). The same study also found that overexpression of 
noggin, a BMP antagonist, had opposite effects. BMP2 and BMP4 have high affinity for 
BMPR1A, and treating mice with a decoy receptor for these BMPs (i.e. a BMPR1A Fc-fusion 
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protein) also led to increased numbers of osteoblasts and reduced numbers of osteoclasts, 
resulting in higher bone mass in these mice (17,18). Supporting these data, conditional deletion 
of Bmpr1a in osteoblast-lineage cells has been shown to increase bone mass in mice (33,34). 
In conclusion, our results that BMP4 has a negative effect on trabecular bone in mice is 
supported by previous reports.   
 
A weakness of our study is the lack of bone histomorphometric data. We can therefore only 
speculate on how BMP4 acted at the cellular level to reduce trabecular bone. Expression of 
mRNA in femurs flushed of bone marrow showed significantly higher expression of Ctsk in the 
AAV8-BMP4 treated mice, which may indicate that there were more osteoclasts in these bones. 
There was, however, a great variation in gene expression within groups and no differences in 
serum CTX-1 levels, so we could not make a conclusion on this matter. While BMPs in bone 
have mainly been studied in relation to effects on the osteoblast lineage, a few studies have 
earlier shown that BMP2, BMP4, BMP5, and BMP6 promote osteoclast differentiation in vitro 
and/or in vivo, supporting our findings (32,35,36). An indirect effect of BMP2 and BMP4 on 
osteoclasts was shown in a study where Bmpr1a was conditionally deleted in osteocytes leading 
to decreased RANKL expression in osteocytes and reduced osteoclast differentiation (33). The 
importance of osteoblastic BMP-signaling for RANKL expression was also shown in other 
studies (17,34). Together these studies and our data presented herein support that BMP-
signaling impacts bone remodeling by influencing both osteoblast and osteoclast 
differentiation. 
AAV mediated gene delivery methods are considered safe and have high gene delivery efficacy 
and are therefore promising tools for gene therapy (37). In adult mice, the same AAV8-BMP4 
vector as used here was shown to increase insulin sensitivity and protected mice on a high-fat 
diet from obesity (22). In line with this study,(22) we found that while control mice had a weight 
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gain of about 5 % in the 8 weeks from viral injections until culling, the weight of BMP4 treated 
mice remained unchanged during the course of the study.  However, it is unlikely that such a 
small difference in body weight will lead to a dramatic effect on trabecular bone. Moreover, in 
the C57BL6/N immunocompetent mice there was no difference in body weight between the 
groups, and we could still observe a reduction in trabecular bone. 
 
Taken together, BMP4 gene therapy inhibited myeloma tumor growth, but also reduced the 
amount of trabecular bone in mice. Care should therefore be taken when considering using 
BMP4 as a therapeutic agent. Whether other BMPs that are also potent inhibitors of multiple 
myeloma cell survival and proliferation will have similar impact on bone remains to be 
investigated. 
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Figure legends 
Figure 1. Experimental set-up. Overview of experimental set up. In brief, 14 weeks old 
RAG2-/- γC-/- mice were implanted with calcium phosphate scaffolds containing human MSCs. 
AAV8-BMP4 or AAV8-CTRL were administered 8 weeks post scaffold implantation by tail-
vein injection (1012 viral particles/100 μL saline/mouse). 10 weeks post implantation 106 
fluorescently labeled KJON myeloma cells were injected into 3 out of 4 scaffolds. Empty 
scaffold refers to scaffold with MSCs, but without tumor cells. 
 
Figure 2. BMP4 inhibited myeloma cell growth in vivo. (A) The myeloma cell line KJON 
was treated with different doses of rmBMP-4. After 48 h, the numbers of viable cells were 
determined by labeling with annexin V-FITC and propidium iodide (PI). (B) The figure shows 
representative dot plots of the results presented in A. Cells in the lower left quadrant, which 
were negative for both annexin V and PI, were considered viable. (C) To estimate tumor burden, 
the amount of near-infrared fluorescent protein (iRFP) in each scaffold was measured weekly 
using the Pearl Imager System in AAV8-CTRL mice (n=30) and AAV8-BMP4 mice (n=27), 
p<0.01, 2-way ANOVA, Bonferroni post test. (D) Representative images of tumor burden in 
AAV8-CTRL (top) and AAV8-BMP4 (bottom) treated mice are shown. (E) Amount of BMP4 
in the serum was estimated at end point by semi-quantitative western blotting. (F) Serum from 
AAV8-CTRL or AAV8-BMP4 mice, 4% final serum concentration, was added to cultures of 
NS0 murine myeloma cells and incubated for 48 h. Reduced cell proliferation, as measured by 
ATP-levels, was counteracted by a BMP4 neutralizing antibody, p<0.0005, Bonferroni post 
test.  
 
Figure 3. BMP4 effect on human and murine bone. (A) Amount of bone/scaffold perimeter 
is presented for both empty and tumor scaffold for AAV8-CTRL treated mice (n=10) and 
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AAV8-BMP4 treated mice (n=9). The left femur from each mouse, AAV8-CTRL (n=10) and 
AAV8-BMP4 (n=9), was harvested and examined by ex vivo µCT. *; p<0.05, 1-way ANOVA, 
Dunn’s multiple comparisons test. (B) Trabecular volume as a proportion of tissue volume 
(BV/TV, %), (C) trabecular number (Tb. N, mm−1) and (D) trabecular separation (Tb.Sp, mm) 
was assessed. Error bars represent SEM. *; p<0.05, ***; p<0.005, two-tailed unpaired t-test. 
(E) Representative images for an AAV8-CTRL mouse and an AAV8-BMP4 mouse are shown. 
Femur cDNA from AAV8-CTRL mice (n=10) and AAV8-BMP4 mice (n=8) was used for 
comparative RT-PCR using TaqMan Assays for the osteoclast specific markers Ctsk (F) and 
Nfatc1 (G). The relative gene expression was analyzed using the ΔΔCt method with Gapdh as 
housekeeping gene. *; p<0.05, two-tailed unpaired t-test. (H) Cells were differentiated with M-
CSF (30 ng/mL) in the presence or absence of rmBMP4 as indicated. TRAP positive cells with 
more than 2 nuclei were counted as osteoclasts. Presented is the mean of three independent 
experiments and error bars represent SEM. *; p<0.05, 1-way ANOVA, Dunn’s multiple 
comparisons test. 
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Table 1. Trabecular bone parameters in untreated RAG2-/- γC-/- vs AAV8-BMP4 mice. 
 
 
 Mean ± SEM p-value (Unpaired t-test) 
 AAV8-CTRL RAG2-/- γC-/- AAV8-CTRL vs RAG2-/- γC-/- 
BV/TV (%) 2.425±0.55 3.291±0.94 0.412 
Tb.Th (mm) 0.05684±0.00 0.05575±0.00 0.5448 
Tb.Sp (mm) 0.4873±0.03 0.4668±0.04 0.6882 
Tb.N/mm 0.4166±0.09 0.5843±0.16 0.3302 
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